delphiwp

In this session, you’ll learn about the essential organizations and activities we must focus on now to ensure psychedelics can be brought to scale as soon as possible after FDA approval.

An Introduction to Delphi, Our Work, and Our Vision for an Integrated Future Welcome to the first in a series of strategic insight sessions from Delphi. I’m Lia Mix, founder and CEO of Delphi, and I’m delighted to share our perspective on what it will take to move psychedelic therapies from promise to practice within our healthcare system, as well as Delphi’s unique role in this critical endeavor. We dedicate this first session to Amanda Fielding, an elder who recently left this Earth, but whose resonance is carried in all who knew and loved her. Amanda’s life’s work will continue to infuse millions of lives with goodness and grace, just as she did in life. Truly, our work at Delphi would not be possible without the courageous work of the many who have come before us. Thank you, Amanda, for all your blessings. You will be dearly missed. Today’s session